Clinical trials: Hepatic Cirrhosis
Liver Cirrhosis, Hepatocellular Carcinoma
Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients
Prospective multicenter cohort recruiting consecutive patients from 7 hospitals in Andalusia, southern Spain, according to following criteria: 1) HIV infection, 2) Chronic active HCV infection, 3) Older than 18 years, 4) New…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, HIV, HCV Coinfection
- Trial name
- NCT02693847
- Where
- 8 sites in Spain
- Volunteers
- 446 people
- Sponsor
- Hospital Universitario de Valme
Thrombocytopenia Related to Chronic Liver Disease
Effect of Rifaximin on Thrombocytopenia in Patients With HCV-Related Liver Cirrhosis
Cirrhosis is a common complication of chronic hepatitis C virus (HCV) infection in Egypt. Thrombocytopenia (TP) is the most common cytopenia in patients with cirrhosis and may be associated with variceal bleeding, rebleeding…
- Trial name
- NCT07791940
- Testing
- Rifaximin (drug)
- Where
- 2 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- Fayoum University Hospital
Clinically Significant Portal Hypertension
The Effect of Sorafenib on Portal Pressure
Sorafenib is approved by the US FDA for the treatment of unresectable (can not operate) liver cancer and for renal cell carcinoma.
- Trial name
- NCT01714609
- Testing
- Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Porto-sinusoidal Vascular Liver Disorder, Liver Cirrhosis
Multiparametric Ultrasound for the Noninvasive Diagnosis of Porto-sinusoidal Vascular Liver Disorder
Porto-sinusoidal vascular disease (PSVD) is a rare clinical entity characterized by significant portal hypertension in the absence of cirrhosis on liver histology, which may or may not show specific alterations of the portal…
- Conditions
- Porto-sinusoidal Vascular Liver Disorder, Liver Cirrhosis, Portal Hypertension, Noncirrhotic, Portal Hypertension Related to Cirrhosis
- Trial name
- CEUS-PSVD (NCT07492862)
- Testing
- Evaluation of quantitative perfusion parameters at dynamic contrast-enhanced ultrasound through Vuebox Software
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Chronic Hepatitis C, Hepatitis C Virus
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
This open-label study will evaluate safety, pharmacokinetics and efficacy of a 12 or 24-week regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in HCV-genotype 1-infected subjects with an…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis, Severe Renal Impairment
- Trial name
- NCT02207088
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, Ribavirin
- Volunteers
- 68 people
- Sponsor
- AbbVie
Glucose Metabolism Disorders
Cirrhosis-Diabetes
Glucose metabolism disorders (GMD) can be present in an overt and a subclinical way. They have negative impact in survival of patients with liver cirrhosis (LC).
- Trial name
- CH-DM (NCT01396954)
- Volunteers
- 130 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Cirrhosis of the Liver
Composition for Treating Cirrhosis and Liver Cancer (SB-1121)
The composition treats cirrhosis and hepatocellular carcinoma (Hcc) at an early stage. The product is extracted from herbs, including Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens…
- Trial name
- SB-1121 (NCT05178303)
- Testing
- SB-1121(1), SB-1121(2)
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Nguyen Thi Trieu, MD
Hepatocellular Carcinoma, Chronic Liver Disease
Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients
By 2030, hepatocellular carcinoma (HCC) will become the second leading cause of cancer-related death, accounting for more than one million deaths per year according to the World Health Organization.
- Trial name
- STARHE (NCT04802954)
- Testing
- Video acquisition
- Where
- 6 sites in France
- Volunteers
- 400 people
- Sponsor
- IHU Strasbourg
Liver Disease, Cirrhosis
Resting Energy Expenditure in Patients on the Waiting List for Liver Transplantation
Metabolic disorders and malnutrition are well known and have been reported in patients with chronic liver disease, but the relationship of energy metabolism and changes in nutritional status in patients on the waiting list for…
- Trial name
- NCT01761851
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Federal University of Minas Gerais
Chronic Hepatitis B, Hepatic Steatosis
Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B
The aim of the study was to evaluate the consistency between liver biopsy and Liver Stiffness Measurement (LSM) for fibrosis and controlled attenuation parameter (CAP) for steatosis in FibroScan® in patients with chronic…
- Trial name
- Faraday (NCT06573190)
- Testing
- Transient elastography, Tenofovir Disoproxil Fumarate
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Yaşar Bayındır, MD
End-Stage Liver Diseases
Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues.
- Trial name
- NCT06984497
- Testing
- Infusion of umbilical cord-mesenchymal stem cells through peripheral veins, Infusion of umbilical cord-mesenchymal stem cells through hepatic artery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- General Hospital of Shenyang Military Region
Primary Biliary Cholangitis, Heart Failure
Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions
Chronic physical conditions are defined as conditions that require ongoing management and treatment over extended periods of time.
- Conditions
- Primary Biliary Cholangitis, Heart Failure, Digestive Diseases, Women Who Have Experienced a Cardiac Event
- Trial name
- EMPOwer (NCT05786482)
- Testing
- Online mind-body wellness program, Online mind-body wellness program + Weekly Check-ins
- Where
- Canada
- Volunteers
- 825 people
- Sponsor
- University of Alberta
Cirrhosis With Hepatocellular Carcinoma
Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma.
- Trial name
- ECHEF (NCT07189624)
- Testing
- Exercise
- Where
- 2 sites in France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Clermont-Ferrand
Decompensated Cirrhosis
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural…
- Trial name
- NC-CHRM (NCT07131280)
- Testing
- Gcsf, Darbepoetin, Standard Medical Treatment
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis, Portal Hypertension
Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension
The purpose of this study is to determine whether sapropterin (an oral analogue of tetrahydrobiopterin) could have a role in the treatment of portal hypertension secondary to liver cirrhosis.
- Trial name
- NCT01456286
- Testing
- sapropterin
- Where
- 2 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Cirrhosis, End Stage Liver DIsease
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.
- Conditions
- Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic
- Trial name
- NCT05205954
- Testing
- Hepatology Home Hospital
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Cirrhosis and Coagulation
Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients
Prospectively evaluation of the incidence of thromboembolic events in hospitalized cirrhotic patients. 2. Efficacy and safety of use of bemiparin in preventing peripheral and portal thrombosis. 3. Monitoring antiXa levels.
- Trial name
- BEMI-2015 (NCT02802605)
- Testing
- Bemiparin
- Volunteers
- 225 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Hepatic Encephalopathy, Cirrhosis, Liver
Rifamycin in Minimal Hepatic Encephalopathy
This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
- Trial name
- RIVET (NCT04082780)
- Testing
- Rifamycin SV MMX
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Liver Fibrosis
Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response
This exploratory, randomized, open-label pilot study evaluated gut microbiota, fecal bile acid profiles, inflammatory markers, and fibrosis-related biomarkers in adults with chronic hepatitis B or hepatitis C after viral control.
- Trial name
- SURGIC-Liver (NCT07102979)
- Testing
- Ursodeoxycholic Acid (URSO), Simvastatin
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- Chang Gung Memorial Hospital
Intrahepatic Cholangiocarcinoma
VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway
The investigators study the VEGF signaling in ICC cell lines／human tissues and its mechanism in HCC growth, proliferation and apoptosis.
- Trial name
- icc (NCT01917370)
- Testing
- surgical treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.